## Hosein Kouros-Mehr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10499726/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. Breast Cancer Research, 2015, 17, 83.	5.0	44
2	Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets. PLoS ONE, 2014, 9, e98293.	2.5	105
3	Expression of GATA3 in MDA-MB-231 Triple-negative Breast Cancer Cells Induces a Growth Inhibitory Response to TGFß. PLoS ONE, 2013, 8, e61125.	2.5	27
4	Biomarkers of Residual Disease, Disseminated Tumor Cells, and Metastases in the MMTV-PyMT Breast Cancer Model. PLoS ONE, 2013, 8, e58183.	2.5	35
5	Differentiation Programs in Development and Cancer. , 2012, , 281-292.		0
6	Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends in Molecular Medicine, 2010, 16, 122-132.	6.7	68
7	GATA-3 Links Tumor Differentiation and Dissemination in a Luminal Breast Cancer Model. Cancer Cell, 2008, 13, 141-152.	16.8	314
8	GATA-3 and the regulation of the mammary luminal cell fate. Current Opinion in Cell Biology, 2008, 20, 164-170.	5.4	138
9	Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Molecular Cancer Therapeutics, 2007, 6, 391-403.	4.1	48
10	GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland. Cell, 2006, 127, 1041-1055.	28.9	576
11	Hormonal and local control of mammary branching morphogenesis. Differentiation, 2006, 74, 365-381.	1.9	253
12	AbMiner: a bioinformatic resource on available monoclonal antibodies and corresponding gene identifiers for genomic, proteomic, and immunologic studies. BMC Bioinformatics, 2006, 7, 192.	2.6	29
13	Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Developmental Dynamics, 2006, 235, 3404-3412.	1.8	192
14	Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Molecular Cancer Therapeutics, 2006, 5, 853-867.	4.1	157
15	Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development (Cambridge), 2005, 132, 3923-3933.	2.5	256
16	Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14229-14234.	7.1	463
17	The bioinformatics of microarray gene expression profiling. Cytometry, 2002, 47, 46-49.	1.8	21